Suppr超能文献

“我没有和任何人讨论过”: 苯二氮䓬受体激动剂的长期使用者在治疗物质使用障碍方面的生活体验。

'I haven't discussed anything with anyone': lived experience of long-term users of benzodiazepine receptor agonists regarding their treatment for substance use disorder.

机构信息

Research Unit of Primary Care and Health, Department of General Medicine, Faculty of Medicine, University of Liège, Liège, Belgium.

Hedera, Department of Sociology, Faculty of Political and Social Sciences, Ghent University, Ghent, Belgium.

出版信息

Int J Qual Stud Health Well-being. 2024 Dec;19(1):2424013. doi: 10.1080/17482631.2024.2424013. Epub 2024 Nov 17.

Abstract

INTRODUCTION

Treatment for substance use disorder (SUD) to benzodiazepine receptor agonists (BZRA) can be challenging and lengthy. BZRA are prescribed for anxiety and insomnia, and though guidelines recommend an initial prescription duration of one to four weeks, this is frequently longer. Understanding the multiple challenges associated with withdrawing from BZRA and exploring the nuance and complexities from the patient's perspective is crucial.

METHODS

In this study, we explore the experiences of SUD to BZRA with nineteen users, who have subsequently either stabilized, reduced, or discontinued their usage. The data were analysed using Interpretative Phenomenological Analysis.

FINDINGS

Our study identified five key themes regarding the long-term use of BZRA which address inadequate patient information, strict adherence to prescribed medication, minimal involvement in cessation plans, respecting patient readiness for tapering and personalized tapering approaches.

CONCLUSION

These findings indicate that patients' blind trust in their providers can prevent them from voicing concerns, highlighting the importance of an authentic and collaborative relationship between the patient and healthcare provider, while respecting patient autonomy. The goal-oriented care approach could improve BZRA management by aligning treatment with individual goals, enhancing satisfaction, and addressing the complexities of long-term use and withdrawal.

摘要

简介

治疗物质使用障碍(SUD)到苯二氮䓬受体激动剂(BZRA)可能具有挑战性且耗时较长。BZRA 被开处用于焦虑和失眠,尽管指南建议初始处方持续时间为一到四周,但通常会更长。了解从 BZRA 戒断的多种挑战,并从患者的角度探索细微差别和复杂性至关重要。

方法

在这项研究中,我们探讨了 19 名 BZRA 物质使用障碍患者的经历,他们随后稳定、减少或停止了使用。使用解释性现象学分析对数据进行了分析。

结果

我们的研究确定了五个关于长期使用 BZRA 的关键主题,这些主题涉及患者信息不足、严格遵守规定的药物治疗、在停药计划中几乎没有参与、尊重患者对逐渐减少的准备情况以及个性化逐渐减少的方法。

结论

这些发现表明,患者对提供者的盲目信任可能会阻止他们表达关切,强调患者和医疗保健提供者之间建立真诚和协作关系的重要性,同时尊重患者自主权。目标导向的护理方法可以通过使治疗与个人目标保持一致、提高满意度并解决长期使用和戒断的复杂性来改善 BZRA 的管理。

相似文献

10
Non-Benzodiazepine Receptor Agonists for Insomnia.用于失眠症的非苯二氮䓬受体激动剂。
Sleep Med Clin. 2015 Mar;10(1):57-76. doi: 10.1016/j.jsmc.2014.11.002. Epub 2014 Dec 20.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验